3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Carcinoma, Non-Small-Cell Lung
6
Carcinoma, Renal Cell
5
Carcinoma, Hepatocellular
3
Triple Negative Breast Neoplasms
2
Melanoma
2
Lung Neoplasms
2
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Prostatic Neoplasms
1
Neoplasms
1
Metastatic Non-Squamous Non-Small Cell Lung Cancer
1
Lung Diseases
1
Liposarcoma
1
Head and Neck Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Endometrial Neoplasms
1
Clear-cell metastatic renal cell carcinoma
1
Carcinoma, Transitional Cell
1
Carcinoma, Squamous Cell
1
Carcinoma
1
Advanced or Metastatic Solid Malignancies
1
Advanced Solid Tumors
1
Advanced Solid Tumor
1
Advanced Malignancies
1
Advanced Biliary Tract Cancer
1
Adenocarcinoma
1
Interventions
Cisplatin
178
Paclitaxel
79
Radiotherapy
76
Carboplatin
70
Brachytherapy
69
pembrolizumab
63
Bevacizumab
40
Gemcitabine
28
Radiation
27
Topotecan
26
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
25
Nivolumab
22
Colposcopy
22
human papillomavirus vaccine, L1 type 16, 18
21
Magnetic Resonance Spectroscopy
21
Drug Therapy
20
atezolizumab
19
Platinum
19
Papillomavirus Vaccines
18
Radiotherapy, Intensity-Modulated
17
Docetaxel
17
Taxes
16
Cyclophosphamide
16
Biopsy
16
Early Intervention, Educational
15
1,2-diaminocyclohexaneplatinum II citrate
15
Methods
14
Blood Specimen Collection
14
fludarabine
13
Injections
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Uterine Cervical Neoplasms
×
sitravatinib
×
Clear all
NCT05614453
2023-06-29
ITTACC
Australia New Zealand Gynaecological Oncology Group
Phase 2
Withdrawn